Clinical Sensors Awarded Over $1.5M in NIH Grants to Advance its Nitric Oxide Diagnostic for Sepsis Recognition and Management
RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / April 18, 2017
Clinical Sensors, Inc. announced today that it was awarded two Small Business Research Grants from the National Institutes of Health (NIH). Together, these grants provide over $1.5 million to support the company's continued development and demonstration of its point-of-care device that directly measures a patient's blood nitric oxide level within a few seconds. Nitric oxide is involved in the progression of sepsis, a life-threatening illness where early and rapid recognition is critical to accelerate the administration of life-saving care.
"These two awards will help us demonstrate the clinical impact of our technology, which is designed to directly measure nitric oxide and related metabolites from biological fluids," said Philippe Chemla, Ph.D., CEO at Clinical Sensors. "Our device requires a single blood sample at bedside to quickly deliver this information."
The $1.29 million Phase 2 STTR award extends this work, which includes a clinical study at the Jaycee Burn Center at UNC. Patients with severe burns often develop sepsis, leading to prolonged hospital stays, increased costs, and a higher risk of death.
"This NIH-supported study will use our device to follow 120 patients during their ICU stays and demonstrate the dynamic nature of nitric oxide in these patients," said Jon McDunn, Ph.D., Head of Research and Development at Clinical Sensors. "We are honored to have Dr. Bruce Cairns, Professor of Surgery and Director of the Jaycee Burn Unit, as co-Principal Investigator on the grant to lead the clinical study."
Clinical Sensors also won a $215,000 Phase 1 SBIR award to add the measurement of low molecular weight S-nitrosothiols to its sensor platform. S-nitrosothiols are endogenous compounds that store nitric oxide in the body and are a critical component of redox biology and physiologic homeostasis. Currently, there is not a reliable method to measure these compounds to better assess the role they play in sepsis and other diseases.
Sepsis, the body's overwhelming systemic response to infection, is an all-too-common occurrence in the modern hospital, with over 1.6 million patients diagnosed annually in the United States. One of the most critical factors driving patient outcomes is rapid recognition. For every hour that sepsis diagnosis is delayed, a patient's risk of death increases by over 7 percent. Delayed treatment is believed to play a significant role in many of the over 250,000 deaths that occur each year from sepsis.
About Clinical Sensors, Inc.
Clinical Sensors (www.clinicalsensors.com) is a development-stage company based in Research Triangle Park, N.C. committed to pioneering diagnostic devices that harness the physiologic properties of nitric oxide to improve patient management. Clinical Sensors has been awarded $3.8 million in NIH SBIR/STTR grants since 2014.
Research reported in this press release was supported by the National Institute of Allergy and Infectious Disease and the National Institute of General Medical Sciences of the National Institutes of Health under award numbers R42AI112064 and R43GM122152.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Clinical Sensors, Inc.
Dr. Jon McDunn
Clinical Sensors' CEO, Philippe Chemla, PhD, MBA, will be attending the Redefining Early Stage Investments (RESI) Conference in San Francisco on January 10th, 2017. If you will be in the San Francisco area and would like to connect with Philippe, you may contact him by email here.
Clinical Sensors has been invited to present at the OktoberINVESTfest in NYC on September 28th. This event is hosted by Invest in Bavaria, the agency responsible for investment promotion in Germany's largest state. Select, high quality companies in the life science and IT space are invited to present at the event to showcase commercial opportunities and innovations for financiers. Companies also presenting at OktoberINVESTfest include Sorrento Therapeutics, Heat Biologics, Medigene, Aytu BioScience, Advaxis, BioXcel, and others.
Learn more here.
Clinical Sensors has been selected as one of six finalists for The Big Launch Challenge, a joint initiative by The Launch Place and First Flight Venture Center designed to showcase up-and-coming tech companies. This event aims to assist companies by providing mentorship, prototyping, and follow-on seed financing. Presenters will have an opportunity to win up to $30,000 in awards.
Clinical Sensors' CEO, Philippe Chemla, will be presenting a live pitch at the event on September 20th at RTP Headquarters.
For more information about this event, click here.
Clinical Sensors has been awarded $217,000 from the National Institutes of Health / National Institute of General Medical Sciences. This project, titled "Point-of-Care Nitric Oxide Sensor for Wound Management", will enable Clinical Sensors to evaluate its nitric oxide sensor as a tool to diagnose and monitor chronic wounds.
Philippe Chemla, MBA, Ph.D. has joined Clinical Sensors as Chief Executive Officer. Philippe has led business development initiatives and commercial partnerships in several industries, including life sciences, devices, and Agbiotech. Philippe has helped companies in these spaces evaluate, position, and commercialize new technologies and products.
Prior to joining Clinical Sensors, Philippe served as Vice President of Business Development at Metabolon, Inc. He has held commercial development roles at Fujifilm Diosynth Biotechnology, as well as research management and business development roles at Ciba, Novartis, and Syngenta.
To accomodate accelerating research activity at Clinical Sensors, the company has acquired a new laboratory space at the First Flight Venture Center in Research Triangle Park, NC.
The new labs quadruple the total available bench space for Clinical Sensors, and provide ample room for the growing research team. Clinical Sensors has equipped the space with a suite of state-of-the-art tools and equipment for further developing its sensor technologies.
Dr. Jon McDunn has joined Clinical Sensors as Director of Medical Device Initiatives. Dr. McDunn is an expert in the biology of inflammation, has over 20-years experience in clinical research, and has made significant contributions to the scientific understanding of sepsis pathology. Dr. McDunn brings commercialization and product development experience to Clinical Sensors, having led teams at Incyte Genomics and Metabolon to commercialize medical devices and research services.
Clinical Sensors has been awarded $1.3 million from the National Institutes of Health / National Institute of Diabetes and Digestive and Kidney Diseases through a Phase II SBIR grant, "Improving the Host Response to Implantable Glucose Sensors via Nitric Oxide Release".
Through this project, Clinical Sensors is developing coatings that improve the accuracy and longevity of implanted continuous glucose monitoring (CGM) devices. CGM sensors are being increasingly used to improve glycemic management for diabetics, and our coating has the potential to improve their accuracy and lifetime, and reduce the number of finger stick calibrations required for patients.
Dr. Wesley Storm, Ph.D. has joined Clinical Sensors as Senior Scientist to lead execution of the technical and research objectives of the company. Dr. Storm is a graduate of the Schoenfisch lab and brings expertise in nitric oxide and membrane chemistry, as well as electrochemistry and sensor design.
With Dr. Storm's hire, Clinical Sensors has moved into laboratory space at First Flight Venture Center to further research and development of the company's NO sensor technology.